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Abstract
Introduction: Sepsis leads to microcirculatory dysfunction and therefore a disturbed neurovascular coupling in the
brain. To investigate if the dysfunction is also present in less severe inflammatory diseases we studied the
neurovascular coupling in patients suffering from community acquired pneumonia.
Methods: Patients were investigated in the acute phase of pneumonia and after recovery. The neurovascular
coupling was investigated with a simultaneous electroencephalogram (EEG)-Doppler technique applying a visual
stimulation paradigm. Resting EEG frequencies, visual evoked potentials as well as resting and stimulated
hemodynamic responses were obtained. Disease severity was characterized by laboratory and cognitive parameters
as well as related scoring systems. Data were compared to a control group.
Results: Whereas visually evoked potentials (VEP) remained stable a significant slowing and therefore uncoupling
of the hemodynamic responses were found in the acute phase of pneumonia (Rate time: control group: 3.6 ± 2.5
vs. acute pneumonia: 1.6 ± 2.4 s; P < 0.0005). In the initial investigation, patients who deteriorated showed a
decreased hemodynamic response as compared with those who recovered (gain: recovered: 15% ± 4% vs.
deteriorated: 9% ± 3%, P < 0.05; control: 14% ± 5%). After recovery the coupling normalized.
Conclusions: Our study underlines the role of an early microcirculatory dysfunction in inflammatory syndromes
that become evident in pre-septic conditions with a gradual decline according to disease severity.
Introduction
Modern sepsis concepts and early goal-directed thera-
pies increasingly focus on the microcirculation and its
integrity in inflammatory syndromes [1-5]. A microcir-
culatory dysfunction was found in many organs such as
gut, heart, lung, and brain [6-8]. Nowadays, the occur-
rence of a microcirculatory dysfunction is regarded as
an important motor of sepsis-associated organ dysfunc-
tion [1-4,8]. Clinically, the microcirculatory dysfunction
correlates with an increased mortality rate and worse
outcome [9-12].
The brain lacks relevant oxygen or energy stores and
therefore is highly dependent on an adequate blood sup-
ply [13]. The neurovascular coupling (NC) is a brain-
intrinsic vasoregulatory mechanism that adapts the local
cerebral blood flow in accordance with the metabolic
needs of active neurons. Neurovascular uncoupling due
to microvascular dysfunction results in an inadequate
blood supply of active neurons and is assumed to be a
relevant factor of sepsis-associated encephalopathy
[14-18].
Since most investigations regarding the brain microcir-
culation were performed in patients with sepsis, the ques-
tion of whether a microvascular dysfunction is even
present in less severe inflammatory syndromes arises.
Community-acquired pneumonia (CAP) is a frequent and
important inflammatory disease with a high risk to run
into a sepsis syndrome [12,19]. We aimed at investigating
patients with CAP in the acute phase and after recovery
and compared data with a control group of similar age.
Disease severity was specified by different intensive care
and pneumonia scoring systems. By applying visual sti-
muli, a simultaneous electroencephalogram (EEG)-
Doppler technique allowed investigation of the NC by
evaluating visually evoked potentials (VEPs) together with
the resultant evoked flow velocity responses. Cognitive
integrity was screened by the Glasgow Coma Scale (GCS)
and Intensive Care Delirium Screening Checklist (ICDSC).
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Materials and methods
Inclusion criteria and examination protocols
The local ethics committee of the Justus-Liebig Univer-
sity of Giessen approved this non-interventional study,
which was performed in accordance with the ethical stan-
dards of the Declaration of Helsinki (1975). All subjects
were informed about the study and gave written
informed consent to participate. The study compared a
patient group suffering from CAP with a healthy control
group of similar age. Consecutively, patients admitted to
the internal department for stationary CAP therapy were
included. Excluded were patients with disturbances of
the visual system, with previous stroke, or with signifi-
cant stenoses of the posterior cerebral circulation as
examined by transcranial Doppler. Patients with malig-
nancies or pulmonary, renal, cardiac, or hepatic organ
failure were also excluded. For technical reasons, patients
with an insufficient temporal bone window hampering
the Doppler recording were disregarded. A first examina-
tion was performed on the day following admittance
when the therapeutic regimen was fixed and the patients
were under antibiotic medication according to the thera-
peutic guidelines of CAP [19]. In all patients, fever was
treated with antipyretics to normalize body temperature.
A second examination was undertaken after a minimum
of 7 days when patients already recovered but were still
under the same medication.
The diagnostic workup included a clinical examination
and technical and laboratory tests. Clinical examination
included auscultation of the chest (presence of inspiratory
crackles) and determination of the respiratory rate and
arterial blood pressure (measured with a cuff technique on
the upper arm). Laboratory tests included leukocyte num-
bers, C-reactive protein (CRP) level, and blood gas analysis
and were performed on the day of the EEG-Doppler test.
Finally, a chest x-ray was done to detect pulmonary infil-
trates. Vascular risk factors that could interfere with vas-
cular function - such as body mass index, smoking habit
(measured in pack-years), hyperlipidemia, hypertension,
coronary artery disease, and diabetes mellitus - were also
obtained. Also, the medication with angiotensin-convert-
ing enzyme or angiotensin receptor blocker, diuretics, sta-
tins, calcium antagonists, glucocorticoids, beta-blocker,
beta-mimetics, theophylline, platelet aggregation inhibi-
tors, nitrates, prostaglandins, or sympathomimetics was
obtained.
To score the disease severity, we chose the Acute Phy-
siology and Chronic Health Evaluation II (APACHE II)
score [20]. To assess the severity of the CAP, we used the
pneumonia severity index (PSI) and graded the patients
in a risk score ranging from grade I to V [21]. Also, the
CURB-65 - confusion of new onset (defined as an abbre-
viated mental test score of 8 or less), urea of greater than
7 mmol/L (19 mg/dL), respiratory rate of 30 breaths per
minute or greater, systolic blood pressure of less than 90
mm Hg or diastolic blood pressure of 60 mm Hg or less,
and age of at least 65 years - was obtained [22]. To spe-
cify the degree of dyspnea of the patients, we chose the
American Thoracic Society Scale (ATS) [23]. To gather
cerebral integrity, we obtained the GCS and ICDSC
scores [24].
Stimulation paradigm
We used, as a stimulation paradigm, a modified checker-
board test in which the volunteers focused on a spot in
the center of a 21-inch liquid crystal display stimulation
monitor. The monitor had a picture repetition time of 5
milliseconds (Iiyama Corporation, Kitaowaribe, Nagano,
Japan). The volunteers were sitting quietly at 1 meter from
the monitor. The stimulation protocol consisted of 10
cycles, each with a resting phase of 20 seconds and a sti-
mulating phase of 40 seconds. During resting periods,
volunteers were instructed to close their eyes; during sti-
mulation phases, they had to look at the screen. Changes
between phases were signaled acoustically by a tone. The
stimuli consisted of black and white pictures that alter-
nated with their negatives to induce contrast-based
visually evoked responses. The contrast between white
and black areas was calculated to a c value of 92%. The
present stimulation paradigm was much more comfortable
for the volunteers as compared with a classic checkerboard
pattern [25]. The flickering frequency was set to 1 Hz,
meaning that a picture was shown for 500 milliseconds
followed by its negative for 500 milliseconds. During the
40-second stimulation phase, 80 reversals were performed.
Doppler recording
For the Doppler recording, two 2-MHz probes were
mounted on an individually fitted head-band. In all cases,
the P2 segment of both posterior cerebral arteries was
insonated. Peak systolic blood flow velocities were
recorded by using a Multidop T2 Doppler device (DWL,
Singen, Germany). The reason for evaluating systolic velo-
cities is that the index is less prone to Doppler artefacts.
The beat-to-beat intervals of cerebral blood flow velocity
were interpolated in a linear fashion with a ‘virtual’ time
resolution of 50 milliseconds. To ensure independence
from the insonation angle and to allow comparisons
between volunteers, absolute values were transformed into
relative changes of cerebral blood flow velocity in relation
to the baseline. The baseline was calculated from the
blood flow velocity averaged over a time span of 5 seconds
before the beginning of the stimulation phase and set to
zero. The method and algorithm for analyzing the data
sets in terms of a control system are described in detail
elsewhere [26]. The following parameters were specified: K
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represents the gain, Tv the rate time, ω the undampened
natural angular frequency (natural frequency), and ζ the
attenuation parameter of the system.
The parameters describe the dynamic features of the
NC with an initial rapid upstroke of flow velocity, over-
shoot, and succeeding decay to a stable flow velocity level
above baseline. The gain represents the flow velocity dif-
ference between conditions of rest and activation under
stable hemodynamic conditions. The rate time indicates
the initial steepness of the flow velocity increase. Natural
frequency and the attenuation describe oscillation fea-
tures of the system. The natural frequency is assumed to
represent the tonus and the speed of the system, whereas
the attenuation describes dampening features such as
elastic properties of the vessel wall.
Electroencephalogram recording
From a 16-channel digital EEG (Schwarzer, Munich, Ger-
many), six channels were used for electrical VEP record-
ing of the field potential. Signals were recorded from Fp1
and Fp2, from O1 and O2, and from the ears, A1 and A2.
The reference electrode was set to Fz. The electrodes
were placed according to the positions specified in the
international 10-20 system. Also, an electrocardiogram
was obtained with electrodes placed on both forearms
and digitized with the EEG data. Data were sampled at a
rate of 1 kHz. An online band-pass filter was applied
with a high-pass filter setting of 0.3 Hz and a low-pass fil-
ter setting of 70 Hz. Functionally evoked electrical activ-
ity changes were recorded from the scalp by means of
silver chloride electrodes fixed by an EEG headset. Resis-
tance was kept below 5 kΩ. The resting EEG activity was
Fourier-transformed to calculate the percentage distribu-
tion of the typical EEG bands. The frequencies below 4
Hz were assumed to be in the range of the delta band,
frequencies between 4 and 7 Hz as theta, between 8 and
12 Hz as alpha, and between 13 and 30 Hz as beta waves.
Calculations were performed by the EEG device. VEPs
were calculated offline from the EEG signals. To quantify
the typical peaks from the VEP waveform, the data from
80 stimulations during a 40-second stimulation phase
were averaged. Analysis of typical peaks (N75 and P100)
was performed, and amplitude differences were calcu-
lated [25].
Statistical analysis
Comparing the first and second measurements in patients
with CAP together with the controls, the clinical as well as
VEP and Doppler data were statistically analyzed with a
one-way analysis of variance (ANOVA). Also, the data
between the recovery/deterioration groups were analyzed
by an ANOVA. In case of significance, a paired compari-
son with the Scheffé post hoc test was performed. Normal
distribution was tested with an F test. Alternatively, a non-
parametric Kruskal-Wallis test was used for the tree group
comparison, whereas a Mann-Whitney U test was used to
compare the data comparing the recovery/deterioration
groups. The level of significance was set to a P value of
less than 0.05.
Results
The study included 50 patients with CAP; in 43 of these
patients, a complete data set of both electrical and hemo-
dynamic recordings was eligible for evaluation. Thirty
patients could be examined after recovery, and 24 of
these patients had a complete data set. The second mea-
surement was performed 8.5 ± 1.7 days after the first
examination. Seven patients deteriorated with sepsis and
septic shock. Six patients could not be followed up.
Thirty healthy volunteers in a similar age range served as
controls. The group characteristics, together with clinical
profiles, are presented in Table 1. Patients presented at
admission with a PSI score of 99 ± 27, which corresponds
to a risk score of IV, and with therapy improved signifi-
cantly to 86 ± 24 (P < 0.05), which corresponds to a risk
score of III. The CURB-65 score was around 1.5 ± 0.9 at
admission and improved non-significantly to 1.3 ±
0.9 under recovery. The APACHE II score was initially
13 ± 4 and with therapy improved to 11 ± 4 (P < 0.05).
The ATS score indicated, on admission, a nearly severe
dyspnea, which with recovery significantly improved to a
moderate dyspnea level (2.9 ± 0.8 to 1.9 ± 0.7; P <
0.0001). The GCS score did not significantly differ
between the first and second examinations, whereas the
ICDSC score showed a strong improvement (3 ± 1 to 1 ±
1; P < 0.0001). From the physiological and laboratory
parameters, a significant lowering of the CRP level (95 ±
22 to 23 ± 23; P < 0.0001) and improvement of the oxy-
gen saturation (93 ± 4 to 96 ± 4; P < 0.01) were found,
whereas leukocyte count, temperature, and pH levels did
not differ between first and second examinations. In both
pneumonia groups, the EEG showed a significant drop in
the relative frequency of the alpha band and increases in
the theta and beta bands (Table 1). This was accompa-
nied by a slowing of the peak frequency in the alpha
band and fastening of that in the theta band. In compari-
son with controls, the power in the theta band was signif-
icantly higher in both pneumonia groups.
Table 2 shows the results from the NC test. There was a
significant difference between groups in regard to the
initial dynamic phase of vasoregulation. The rate time
parameter describes the initial speed of flow velocity adap-
tation. The significantly smaller parameter in the acute-
phase group indicates a slower upstroke and therefore a
delayed cerebral blood flow adaptation (Figure 1). With
recovery from pneumonia, a normalization of the
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Table 1 Group data for vascular risk factors, medication, and resting EEG data together with ANOVA statistical results
Acute pneumonia (A) Recovery from pneumonia (R) Control (C) ANOVA
Age, years 67 ± 13 65 ± 11 66 ± 8 NS
Number 43 24 30 -
Female/male ratio 30/13 17/7 16/14 -
RR mean, mm Hg 83 ± 12 86 ± 12 82 ± 14 NS
Body mass index 24 ± 6 28 ± 6 24 ± 6 NS
Smoker, pack-years 46 ± 8 31 ± 13 - NS
Diabetes, percentage 17 14 - NS
Coronary artery disease, percentage 44 29 - NS
Leukocytes, G/L 11 ± 5 10 ± 4 N.O. NS
CRP, mg/dL 95 ± 22 23 ± 23 N.O. P < 0.0001
Temperature,°C 36.7 ± 0.6 36.3 ± 0.3 N.O. NS
pH 7.37 ± 0.06 7.40 ± 0.03 N.O. NS
Hkt, percentage 38 ± 6 38 ± 5 N.O. NS
sO2 percentage 93 ± 4 96 ± 4 N.O. P < 0.01
ATS score 2.9 ± 0.8 1.9 ± 0.7 N.O. P < 0.0001
PSI score 99 ± 27 86 ± 24 N.O. P < 0.05
CURB-65 score 1.5 ± 0.9 1.3 ± 0.9 N.O. NS
APACHE II score 13 ± 4 11 ± 4 N.O. P < 0.05
GCS score 15 ± 0.5 15 ± 0.4 N.O. NS
ICDSC score 3 ± 1 1 ± 1 N.O. P < 0.0001
EEG μV2 delta 82 ± 71 81 ± 58 98 ± 68 NS
EEG μV2 theta 58 ± 62 56 ± 52 26 ± 12 C-A: P < 0.01;
C-R: P < 0.01
EEG μV2 alpha 118 ± 126 126 ± 98 151 ± 128 NS
EEG μV2 beta 40 ± 25 44 ± 24 31 ± 12 NS
EEG percentage delta 30 ± 15 27 ± 13 31 ± 16 NS
EEG percentage theta 19 ± 12 22 ± 11 10 ± 3 C-A: P < 0.001;
C-R: P < 0.0001
EEG percentage alpha 35 ± 17 35 ± 13 47 ± 20 C-A: P < 0.01;
C-R: P < 0.05
EEG percentage beta 16 ± 7 16 ± 9 12 ± 5 C-A: P < 0.05
EEG peak Hz delta 1.2 ± 0.3 1.2 ± 0.4 1.2 ± 0.3 NS
EEG peak Hz theta 6.6 ± 0.9 7.1 ± 0.7 6 ± 0.8 C-A: P < 0.001;
C-R: P < 0.0001
A-R: P < 0.05
EEG peak Hz alpha 9.4 ± 0.9 9.1 ± 0.8 11 ± 0.8 C-A: P < 0.0001;
C-R: P < 0.0001
EEG peak Hz beta 15.9 ± 2 15.6 ± 2.1 15.9 ± 2.2 NS
Data are presented as mean ± standard deviation unless otherwise indicated. ANOVA, analysis of variance; APACHE II, Acute Physiology and Chronic Health
Evaluation II; ATS, American Thoracic Society Scale; CRP, C-reactive protein; CURB-65, confusion of new onset (defined as an abbreviated mental test score of 8 or
less), urea of greater than 7 mmol/L (19 mg/dL), respiratory rate of 30 breaths per minute or greater, systolic blood pressure of less than 90 mm Hg or diastolic
blood pressure of 60 mm Hg or less, and age of at least 65 years; EEG, electroencephalogram; GCS, Glasgow Coma Scale; Hkt, hematocrit; ICDSC, Intensive Care
Delirium Screening Checklist; N.O., nitric oxide; NS, not significant; PSI, pneumonia severity index; RR, blood pressure; sO2, blood oxygen saturation.
Table 2 Neurovascular function test
VEP N1-P1,
μV








Control group 7.6 ± 2.7 45 ± 10 14 ± 5 0.21 ± 0.05 0.49 ± 0.18 3.6 ± 2.5
Acute pneumonia 7.7 ± 3.2 47 ± 13 15 ± 8 0.21 ± 0.08 0.43 ± 0.18 1.6 ± 2.4a
Recovery from
pneumonia
7.2 ± 2.3 45 ± 11 15 ± 6 0.23 ± 0.06 0.50 ± 0.35 3.4 ± 2.4
ANOVA NS NS NS NS NS P < 0.0005
Except for analysis of variance (ANOVA), data are presented as mean ± standard deviation. aIndicates P < 0.01 result of the Scheffé post hoc test. NS, not
significant; VEP, visually evoked potential.
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parameter was seen. The VEP, the resting flow velocity
level, and the other hemodynamic parameter did not differ
between the three groups.
Although the number of patients who deteriorated after
the first examination is limited, a comparison with the
initial data of those patients who recovered revealed a sig-
nificantly higher PSI score, a trend to a higher APACHE II
score, and similar ATS and CURB-65 scores (Table 3).
The GCS score was significantly lower whereas the ICDSC
score could not discriminate between groups. Interest-
ingly, all patients who had a bad outcome had a history of
coronary artery disease. This finding was significant com-
pared with the group that recovered (P < 0.05). Another
significant finding pointing to a worse vascular functioning
was the gain parameter, which was lower in the patient
group with worse outcome. Other indicators for a dete-
rioration were trends to a lower pH level and a lower body
temperature (both P = 0.07) (Table 3). No patient took
nitrates, prostaglandins, or sympathomimetics. Analysis of
the medication revealed no significant difference between
the groups.
Discussion
Patients on admission presented with a grade IV CAP
according to the PSI score and were treated as high-risk
patients on an internal ward. The CURB-65 score was
about 1.5, indicating a lethality risk of between 3% and
13% [23]. The APACHE II score was initially around 13
points, indicating a lethality of 15% [27]. The ATS level
indicated a severe dyspnea confirmed by the oxygen
saturation of 93% ± 4%. Besides showing the typical clini-
cal and laboratory parameters, patients showed a typical
slowing of EEG, mainly into the theta band [28]. Owing
to the sensitivity of the ICDSC, the test could differenti-
ate between the acute phase and the recovery whereas
the GCS was insensitive [24]. However, in the acute
phase, the GCS could give additional information since it
could discriminate between the group that recovered and
that which deteriorated, whereas the ICDSC was positive
in both cases.
The new finding was that the patients with CAP pre-
sented with a neurovascular uncoupling in the acute
inflammatory phase. This was concluded from dissocia-
tion of electrical and hemodynamic data. A significantly
delayed hemodynamic adaptation to cortical activation
(rate time) occurred despite unchanged VEP amplitudes
and latencies. A decreased rate time parameter indicates
a reduced speed of the NC. A change from rest to activa-
tion results in an increase in neuronal activity and thus
metabolic needs in the millisecond range, whereas the
hemodynamic adaptation works in the second range. The
different response times lead to an initial perfusion mis-
match that lasts about 8 to 10 seconds even under phy-
siological conditions but is significantly prolonged in the
acute phase of patients with CAP. Owing to a continu-
ously changing brain activity, the slowing of the NC
leads, on average, to a reduced cerebral perfusion [29].
Patients who deteriorated showed a significantly
decreased gain parameter that further reduced adequate
blood supply of active neurons. Since the PSI score and
Figure 1 The modeled hemodynamic flow velocity responses due to visual stimulation are shown as relative changes to resting flow
velocity. The resting flow velocity level was set to zero. During the acute phase of community-acquired pneumonia (CAP), the initial
hemodynamic responses were delayed, resulting in a lag of blood flow adjustment of about 3 to 4 seconds as compared with the
hemodynamic responses after recovery from CAP. After compensation of the initial mismatch, flow velocity levels did not differ at the end of the
stabilization phase.
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Table 3 Comparison of initial patient data grouped according to improvement or deterioration of clinical conditions
Acute-phase examination Patients who recovered
(n = 24)
Patients who deteriorated (n = 7) Statistics
RR mean, mm Hg 83 ± 13 84 ± 12 NS
Body mass index 28 ± 6 24 ± 4 NS
Smoking, pack-years 31 ± 13 57 ± 20 NS
Diabetes, percentage 14 33 NS
Coronary artery disease, percentage 29 100 P < 0.05
pH 7.37 ± 0.06 7.33 ± 0.04 P = 0.07
Leukocytes, g/L 11 ± 5 11 ± 5 NS
Temperature,°C 36.8 ± 0.6 36.3 ± 0.3 P = 0.07
ATS score 3 ± 0.8 3 ± 0.8 NS
PSI score 101 ± 23 125 ± 13 P < 0.05
CURB-65 score 1.6 ± 0.9 2.0 ± 0.6 NS
APACHE II score 13 ± 4 15 ± 2 P = 0.06
GCS score 15 ± 0.3 14 ± 0.8 P < 0.05
ICDSC score 3 ± 1 3 ± 1 NS
ACE/AT inhibitors, percentage 36 66 NS
Calcium antagonists, percentage 18 17 NS
Beta-blocker, percentage 32 66 NS
Diuretics, percentage 77 100 NS
Statins, percentage 14 33 NS
Thrombo inhibitors, percentage 32 66 NS
Glucocorticoids, percentage 41 33 NS
b2 mimetics, percentage 64 83 NS
Theophylline, percentage 23 17 NS
EEG μV2 delta 83 ± 74 68 ± 43 NS
EEG μV2 theta 60 ± 64 43 ± 41 NS
EEG μV2 alpha 122 ± 131 77 ± 65 NS
EEG μV2 beta 42 ± 27 29 ± 15 NS
EEG percentage delta 30 ± 16 31 ± 11 NS
EEG percentage theta 19 ± 12 19 ± 14 NS
EEG percentage alpha 35 ± 17 33 ± 17 NS
EEG percentage beta 16 ± 7 17 ± 9 NS
EEG peak Hz delta 1.2 ± 0.4 1.3 ± 0.3 NS
EEG peak Hz theta 6.6 ± 0.9 6.3 ± 1 NS
EEG peak Hz alpha 9.3 ± 0.9 9.7 ± 0.9 NS
EEG peak Hz beta 15 ± 2 16.4 ± 2.5 NS
Visual evoked potential, μV 7.4 ± 2.3 7.1 ± 2.8 NS
Resting flow velocity, cm/second 47 ± 14 48 ± 17 NS
Gain, percentage 15 ± 4 9 ± 3 P < 0.05
Natural frequency, 1/second 0.21 ± 0.03 0.22 ± 0.08 NS
Attenuation 0.41 ± 0.19 0.31 ± 0.27 NS
Rate time, seconds 1.6 ± 1.3 0.9 ± 0.3 NS
Data are presented as mean ± standard deviation unless indicated otherwise. ACE, angiotensin-converting enzyme; APACHE II, Acute Physiology and Chronic
Health Evaluation II; AT, angiotensin; ATS, American Thoracic Society Scale; CURB-65, confusion of new onset (defined as an abbreviated mental test score of 8 or
less), urea of greater than 7 mmol/L (19 mg/dL), respiratory rate of 30 breaths per minute or greater, systolic blood pressure of less than 90 mm Hg or diastolic
blood pressure of 60 mm Hg or less, and age of at least 65 years; EEG, electroencephalogram; GCS, Glasgow Coma Scale; ICDSC, Intensive Care Delirium
Screening Checklist; NS, not significant; PSI, pneumonia severity index; RR, blood pressure.
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the other disease parameters were also increased in that
group, it appears that the drop in the gain parameter
might be related to the stronger inflammatory process.
The present results mimic animal sepsis experiments in
which a vascular uncoupling preceded changes in evoked
potential amplitudes and in which the uncoupling was
dependent on the severity of inflammatory induction
[14]. Although the findings were discrete, the uncoupling
might have clinical relevance since it was shown that a
cerebral perfusion mismatch of only 10% results in pro-
tein synthesis disturbances and dysfunction of neurons
[8]. Though indicative of a disturbed NC, the matter with
the reduced gain parameter and its relation to the CAP
has to be addressed in more detail. Since we do not have
data from the patients in the group that deteriorated
under non-inflammatory conditions, the high frequency
of coronary artery disease in this group gains relevance.
Each patient in the deteriorating group had a history of
coronary artery disease, whereas in the recovery group,
this was only in 29% of cases. It is known that the severity
of the coronary artery disease is correlated with a
decreased gain parameter [30]. However, patients with
previous vascular diseases are known to be more prone
to a more severe sepsis syndrome and worse outcome
[1-3]. Therefore, the possibility exists that the reduced
gain parameter was caused by a more severe athero-
sclerosis rather than by a more pronounced inflamma-
tion. Anyway, both explanations point to a pivotal role of
the vascular system and microcirculation in inflammatory
syndromes.
At early phases of an inflammatory syndrome, the
microcirculatory dysfunction could not be concluded
from systemic hemodynamic indices such as blood pres-
sure or overall organ perfusion, because their correlation
is very loose [8,9]. We also did not find a significant dif-
ference between groups in regard to the blood pressure
or cerebral resting flow velocities. Only with functional
activation experiments were we able to unmask a micro-
circulatory dysfunction in the visual cortex.
The present technique using visual stimuli has another
advantage in comparison with other studies, which have
used acetazolamide or carbogene gas to assess microvas-
cular reactivity in patients with sepsis [31,32]. Both
agents induce a shift in the interstitial pH level, which is
the trigger for the microvascular reaction. Since the sep-
sis itself leads to considerable pH changes, this might
bias test results [33,34].
A limitation of the present study might be the relatively
small patient number, so the present findings have to be
corroborated in studies with a bigger sample size. How-
ever, owing to the simultaneous investigation of electrical
and hemodynamic responses, the technique has a higher
sensitivity in comparison with other studies in which
serial investigations have been performed. Furthermore, a
clinically feasible tool should allow individual examina-
tions. The present EEG-Doppler approach meets these
recommendations and its sensitivity has been demon-
strated in other clinical investigations.
Conclusions
It appears from the present study that the occurrence of
a microcirculatory dysfunction seems to gradually
depend on the severity of the inflammatory process.
Since patients with vascular diseases have a smaller
compensative range, they might be at higher risk, possi-
bly explaining their worse outcome in sepsis syndromes.
Our data support modern guidelines that recommend a
microvascular monitoring of patients in early stages of
inflammatory syndromes.
Key messages
• Neurovascular uncoupling occurs early in patients
with community-acquired pneumonia.
• Firstly, neurovascular uncoupling results in a slow-
ing of the initial hemodynamic blood flow adaptation
(rate time parameter) whereas the level of the blood
flow velocity change under stabilized hemodynamic
conditions remains constant (gain parameter).
• Secondly, a decline in the gain parameter occurs in
cases that are more severe.
• Our data support concepts of a critical role of a
microcirculatory dysfunction as a motor of sepsis-
associated encephalopathy.
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